Efficacy of Sustained-Release Bupropion in Neuropathic Pain: An Open-Label Study

Semenchuk, Marilyn R.; Davis, Bennet

doi:10.1097/00002508-200003000-00002

Cited by 46 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analgesic effects in neuropathic pain have also been suggested for a newer mixed reuptake inhibitor, duloxetine (Cymbalta ™ ; Eli Lilly and Company; Indianapolis, IN). Bupropion (Wellbutrin ® ; GlaxoSmithKline; Research Triangle Park, NC), a noradrenergic compound, also is analgesic in neuropathic pain [24,25] and often is activating. The latter effect can be particularly helpful in the hypoactive depressed, sedated, or fatigued patient often encountered in the cancer population [26].…”

Section: Other Antidepressantsmentioning

confidence: 99%

Adjuvant Analgesics in Cancer Pain Management

2004

View full text Add to dashboard Cite

Adjuvant analgesics are defined as drugs with a primary indication other than pain that have analgesic properties in some painful conditions. The group includes numerous drugs in diverse classes. Although the widespread use of these drugs as first-line agents in chronic nonmalignant pain syndromes suggests that the term "adjuvant" is a misnomer, they usually are combined with a less-than-satisfactory opioid regimen when administered for cancer pain. Some adjuvant analgesics are useful in several painful conditions and are described as multipurpose adjuvant analgesics (antidepressants, corticosteroids, α α 2 -adrenergic agonists, neuroleptics), whereas others are specific for neuropathic pain (anticonvulsants, local anesthetics, N-methyl-D-aspartate receptor antagonists), bone pain (calcitonin, bisphosphonates, radiopharmaceuticals), musculoskeletal pain (muscle relaxants), or pain from bowel obstruction (octreotide, anticholinergics). This article reviews the evidence supporting the use of each class of adjuvant analgesic for the treatment of pain in cancer patients and provides a comprehensive outline of dosing recommendations, side effects, and drug interactions. The Oncologist 2004;9:571-591

show abstract

Section: Other Antidepressantsmentioning

confidence: 99%

Adjuvant Analgesics in Cancer Pain Management

2004

View full text Add to dashboard Cite

show abstract

“…• Although less extensively studied than the previously mentioned antidepressants, there are some data from open-label studies to suggest the utility of bupropion and nefazodone for selected pain states such as neuropathy and headache [43,44,Class II]. Nefazodone use has been linked with hepatic dysfunction, and its use should be avoided in patients taking concurrent medications with potential hepatotoxic effects (acetaminophen).…”

Section: Other Antidepressantsmentioning

confidence: 99%

Chronic pain and comorbid depression

Leo

2005

Curr Treat Options Neurol

View full text Add to dashboard Cite

For patients with chronic pain, the experience of pain is intimately linked with psychologic distress. Epidemiologic studies indicate that depression is a common comorbidity accompanying chronic pain states. Longitudinal studies also suggest that depression can predict the emergence of chronic pain in selected populations. Emerging evidence suggests numerous pathophysiologic mechanisms that underlie the coexistence of depression and chronic pain states. Comorbid depression can complicate the presentation, clinical course, and response to treatment of patients with chronic pain. The literature reviewed herein focuses on treatment approaches applicable to chronic, nonmalignant pain states predominantly. Although antidepressants offer advantages in simultaneously producing pain relief and mitigating depression, not all antidepressants share equal efficacy; those with noradrenergic and serotonergic influences seem to fare better than agents with single neurotransmitter influences. Treatment of depression may be essential to fully enlist the patient with chronic pain in comprehensive pain management and rehabilitative approaches. Management plans of patients with chronic pain can be designed with specific individual patient needs in mind, and may involve concurrent use of antidepressants, analgesics, and psychotherapeutic approaches.

show abstract

“…The NNT was 2.6 for tricyclics, 6.7 for SSRIs, 2.5 for the anticonvulsant sodium channel blockers, 4.1 for the anticonvulsant calcium channel blocker gabapentin, and 3.4 for the mixed opioid and monoaminergic drug tramadol. The reviews of antidepressant analgesia suggest that antidepressants with both serotonin and norepinephrine reuptake inhibition show the greatest analgesic effect [60••,61] and norepinephrine reuptake inhibition may be crucial for relief in diabetic and postherpetic neuralgia [62].…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

“…There is only one open-labeled study on bupropion in pain [62], in which there were significant reductions in pain levels at the end of 8 weeks. Bupropion, because of its norepinephrine reuptake blockade, has the potential for being an analgesic antidepressant, although this remains to be studied conclusively.…”

Section: Dopamine-norepinephrine Reuptake Inhibitorsmentioning

confidence: 99%

The psychopharmacologic treatment of depression and anxiety in the context of chronic pain

Verma

Gallagher

2002

Current Science Inc

View full text Add to dashboard Cite

Chronic pain afflicts millions of people, commonly causing depression and anxiety. These conditions must be treated to achieve a good functional outcome from pain treatment. Selective serotonin reuptake inhibitors, tricyclics, and newer antidepressants effectively treat both depression and selected anxiety disorders. Antidepressants with noradrenergic and serotinergic activity, and anticonvulsants, which may also stabilize mood, are effective in neuropathic pain. Other medications have limited but important pharmacotherapeutic roles.

show abstract

Efficacy of Sustained-Release Bupropion in Neuropathic Pain: An Open-Label Study

Cited by 46 publications

References 27 publications

Adjuvant Analgesics in Cancer Pain Management

Adjuvant Analgesics in Cancer Pain Management

Chronic pain and comorbid depression

The psychopharmacologic treatment of depression and anxiety in the context of chronic pain

Contact Info

Product

Resources

About